GATA2 and acute myeloid leukemia: We did not detect any EIF6 mutations in control cohorts, including patients with SDS-L disease (n = 11), patients with other leukemia predisposition disorders (germline GATA2 deficiency syndrome, n = 32; telomere biology disorders, n = 5; germline SAMD9/SAMD9L mutations, n = 5), or adults with sporadic AML (n = 39).